0001181431-12-023609.txt : 20120411 0001181431-12-023609.hdr.sgml : 20120411 20120411130742 ACCESSION NUMBER: 0001181431-12-023609 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120404 FILED AS OF DATE: 20120411 DATE AS OF CHANGE: 20120411 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hora Maninder CENTRAL INDEX KEY: 0001443159 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 12753805 MAIL ADDRESS: STREET 1: PDL BIOPHARMA, INC. STREET 2: 1400 SEAPORT BOULEVARD CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 3 1 rrd341771.xml X0205 3 2012-04-04 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001443159 Hora Maninder 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP Pharma Dev and Mfg Common Stock 600 D Employee Stock Option 13.70 2018-08-01 Common Stock 180000 D Employee Stock Option 10.69 2019-02-07 Common Stock 30000 D Employee Stock Option 7.21 2020-02-07 Common Stock 62500 D Employee Stock Option 7.21 2020-02-07 Common Stock 62500 D This option was granted on August 2, 2010 and vests as to 25% of the option on the first anniversary of the grant date and as to the remaining 75% of the option in monthly installments over the three-year period thereafter. This option was granted on February 8, 2011 and vests in monthly installments over the four-year period following the grant date. This option was granted on February 8, 2012 and vests in monthly installments over the four-year period following the grant date. This option was granted on February 8, 2012 and is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the option becomes vested and exerciseable. Under the time-based vesting requirement, the option vests in monthly installments over the four-year period following the grant date. The performance-based vesting condition will be met only if Nektar (or a licensee), within 5 years following the grant date, files a new drug registration with the U.S. FDA or the European Medicines Agency for a significant drug candidate program. Gil M. Labrucherie - Attorney-in-Fact 2012-04-11